- Trial phase
- Phase 3
- Time to market
- The Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.
- Why 5/10
- The next hard, dated catalyst is the ASH 2026 oral presentation of updated Phase 1/2 ReInspire data in vascular anomalies on December 14, 2026, followed by a company conference call with a regulatory update. This is not a pivotal readout or PDUFA decision; the main value driver (Phase 3 breast cancer) readout is more than 12 months away.
The ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.
Price Chart
Executive Summary
Zovegalisib is Relay Therapeutics' lead asset, a first-in-class allosteric, mutant-selective PI3K-alpha inhibitor in Phase 3 for PIK3CA-mutant HR+/HER2- metastatic breast cancer. It received FDA Breakthrough Therapy Designation in February 2026. Early clinical data showed a 43% objective response rate and median 11.1-month progression-free survival with a favorable safety profile that avoids the hyperglycemia typical of older PI3K-alpha inhibitors. The company has $849 million in cash (runway into 2029), strong institutional backing (FMR LLC, BlackRock, State Street all added significantly), and 18 analysts rate the stock a strong buy with a mean price target of $27.58 (50% upside). The next catalyst is an oral presentation at ASH on December 14, 2026, with updated vascular anomaly data and a regulatory update.
How It Works
Zovegalisib is an oral small molecule designed to selectively inhibit mutant forms of PI3K-alpha (PI3K-alpha), a protein that drives cancer cell growth. Unlike older PI3K-alpha inhibitors such as alpelisib and inavolisib, which block both normal and mutant PI3K-alpha and cause side effects like high blood sugar, zovegalisib selectively targets only the mutant form by binding to a different site on the protein. This selectivity is designed to preserve normal PI3K-alpha function and reduce toxicity.
Trial Status
Zovegalisib is in a global Phase 3 registrational trial (ReDiscover-2) testing zovegalisib + fulvestrant versus capivasertib + fulvestrant in PIK3CA-mutant, HR+/HER2- advanced breast cancer, which began enrollment in mid-2025 with enrollment expected to complete in mid-2027. A separate Phase 3 frontline trial in endocrine-sensitive patients is expected to initiate in early 2027. A Phase 1/2 ReInspire trial in vascular anomalies is ongoing, with updated data to be presented at ASH on December 14, 2026. A Phase 2 trial in PIK3CA-related overgrowth spectrum (PROS) is also enrolling.
The Two-Sided Case
Upcoming Catalysts
- ASH 2026 oral presentation of updated ReInspire data in vascular anomalies on December 14, 2026, with company call with regulatory update.
- Phase 3 ReDiscover-2 enrollment completion expected mid-2027.
- Phase 3 frontline breast cancer trial expected to initiate in early 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Relay Therapeutics, Inc. PRESS-RELEASE RLAY ·Originating report